Disease-free survival
Figure 3 · Panel Disease-free_survival
Panel Disease-free_survival 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Ulrich Güller, Stefanie Hayoz, Daniel Horber, Wolfram Jochum, Sara De Dosso, Dieter Koeberle, Sabina Schacher, Roman Inauen, Michael Stahl, Thierry Delaunoit, Thomas Ettrich, György Bodoky, Pierre Michel, Thibaud Koessler, Karin Rothgiesser, Sandra Calmonte, Markus Joerger
Clin Cancer Res 31(15) 3142-3149
PURPOSE: We assessed the benefit of adjuvant aspirin in patients with resected phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated colon cancer. PATIENTS AND METHODS: This was a phase III, prospective, randomized, placebo-controlled, double-blind, multicenter, and multinational trial. Patients with resected colon cancer stage II and III harboring an activating PIK3CA mutation were included. Because of financial constraints, the trial was prematurely closed. Randomization was 2:1 to aspirin 100 mg versus placebo daily for 3 years. The primary endpoint was disease-free survival (DFS). Secondary endpoints included the time to disease recurrence (TTR), overall survival, and adverse events. RESULTS: Overall, 1,040 patients were screened for PIK3CA mutations, with 112 randomized to aspirin (N = 74) and placebo (N = 38). The median age was 66 years, and 42.9% were female. After a median follow-up of 4 years, 19 DFS events occurred, including 10 in the aspirin and nine in the placebo arm. The HR for DFS was 0.57 [90% confidence interval (CI), 0.27-1.22], in favor of aspirin (P = 0.11). DFS rates at 5 years were 86.5% (90% CI, 77.7%-92.0%) in the aspirin and 72.9% (90% CI, 55.7%-84.3%) in the placebo arm. The HR for TTR was 0.49 (90% CI, 0.21-1.19, P = 0.089) in favor of aspirin. No patient experienced aspirin-related serious adverse events. CONCLUSIONS: The SAKK 41/13 is the first randomized trial to provide clinical evidence of a protective effect of adjuvant aspirin in patients with resected PIK3CA-mutant colon cancer, with clinically relevant DFS and TTR improvements. Although results were not statistically significant because of premature study closure, adjuvant aspirin warrants individual consideration in patients with resected PIK3CA-mutant colon cancer stage II and III. See related commentary by Drew et al., p. 3107.
2 个 Figure · 2 个 KM 面板
Figure 3. Disease-free survival. Kaplan-Meier curve of disease-free survival (including unstratified hazard ratio) – comparison between patients randomized to aspirin (in red) versus placebo (in blue). Abbreviation: HR: hazard ratio
Figure 3 · Panel Disease-free_survival
Panel Disease-free_survival 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4. Time to recurrence. Kaplan-Meier curve of time to recurrence (including unstratified hazard ratio) – comparison between patients randomized to aspirin (in red) versus placebo (in blue). Abbreviation: HR: hazard ratio
Figure 4 · Panel Time_to_recurrence
Panel Time_to_recurrence 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。